Jubilant Pharmova jumps after reporting turnaround Q4 performance
Jubilant Pharmova rallied 4.54% to Rs 947.05 after the company reported net profit of Rs 153.60 crore in Q4 FY25 compared with net loss of Rs 58.60 crore in Q4 FY24.
Revenue from operations increased 9.7% YoY to Rs 1,915.80 crore in Q4 FY25.
The company reported pre-tax profit of Rs 206 crore in Q4 FY25 as against pre-tax loss of Rs 53.70 crore in Q4 FY24.
EBITDA jumped 23% to Rs 357 crore during the quarter compared with Rs 289 crore in Q4 FY24. EBITDA margin expanded 210 bps to 18.4% in Q4 FY25 as against 16.3% in Q4 FY24.
In Q4 FY25, radiopharmaceuticals revenue grew by 15% YoY to Rs 296 crore, while revenue from radio pharmacy increased 7% YoY to Rs 600 crore in Q4 FY25. Revenue from Allergy Immunotherapy rose 2% YoY to Rs 192 crore and CDMO sterile injectables grew by 31% YoY to Rs 340 crore during the quarter .
Contract research, development and manufacturing organisation (CRDMO) revenue stood at Rs 338 crore in Q4 FY25, up 19.86% YoY. The generics business reported revenue of Rs 157 crore in Q4 FY25, reflecting a 22% YoY decline.
On full year basis, the companys consolidated net profit surged 988.7% to Rs 839.40 crore on 8.2% increase in revenue from operations to Rs 7,192.10 crore in FY25 over FY24.
On the outlook front, in the Radiopharmaceuticals business, the company expects continued growth in Ruby-Fill installations. It remains on track to launch multiple new products in PET and SPECT imaging between FY27 and FY29. The dosing for the Phase 2 clinical trial of MIBG has been completed, and the data package is being prepared for submission to the US FDA by the second half of FY26. On the therapeutic front, over 10 new products are expected to be commercially available starting in 2029, supporting the expansion of the PET imaging industry. The proposed investment in six radiopharmacies is progressing, with commercial operations expected to begin from FY28 onwards.
In the Allergy Immunotherapy segment, the company, as the sole supplier of Venom in the US, is working to expand the market by enhancing customer awareness. Revenue continues to grow in the US allergenic extracts business, and efforts are underway to penetrate markets beyond the US.
In the CDMO Sterile Injectables segment, the capacity expansion at the Spokane, Washington facility is on schedule. Line 3 and Line 4 are expected to commence commercial production in late FY26 and FY28, respectively. Peak utilisation for Line 3 is now anticipated within three years of commercial launch, ahead of the earlier estimate of four years.
In the CRDMO business, the medium-term outlook continues to be positive. In the short term, the business is trying to diversify its customer base and for the medium term, it is adding development capabilities in addition to research and manufacturing. In the CDMO API segment, efforts are concentrated on improving capacity utilisation through CDMO projects and custom generics manufacturing.
In the Generics business, the company plans to launch six to eight products per annum in across US and non-US international markets. Export volumes to the US are being scaled up gradually and meaningfully, with increased contributions expected from contract manufacturing partners. The business aims to enhance profitability and return to growth in FY26.
In the Proprietary Novel Drugs segment, interim data from the Phase 2 trial of JBI-802 is anticipated in FY26.
Shyam. S. Bhartia, chairman Jubilant Pharmova and Hari S Bhartia, co-chairman & non-executive director, said, We are pleased to announce revenue of Rs 7,235 crore in FY25, growth of 8% over last year. We delivered robust revenue growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables and CRDMO businesses. EBITDA grew by 24% to Rs 1,230 crore on the back of strong operating performance across all business units. EBITDA margins for the year expanded by 220 basis points. Reported PAT grew by 1,050% to Rs 836 crore, while normalised PAT grew by 112% to Rs 415 crore on the back of improved operating performance and reduced finance cost. Net Debt / EBITDA reduced from 2.5x in Mar24 to 1.1x in Mar25 on the back of voluntary debt prepayment of USD 125 million in FY25.
In Feb2025, we outlined our Vision 2030, which is to double our revenues from FY24 to FY30, improve EBITDA margins to 23% to 25% range, reduce Net debt to zero and grow Return on Capital to high teens. Our FY25 financial performance takes us one-step closer to our Vision.
During the year, the company started distributing Pylarify, an industry leading prostate cancer diagnostic imaging agent from PET radiopharmacies, completed Media Fills on Line 3 in CDMO Sterile Injectables, added strategic capabilities in the area of Biologics and Antibody drug conjugates in Drug Discovery, reached profitability in the Generics business and dosed first patients in JBI-802 and JBI-778 clinical trials.
The large innovator pharma companies, for their US requirements, are now looking to create an alternate manufacturing site in the US as a risk management measure in the event of tariff imposed by the US govt. Therefore, the company is starting to see excellent traction in the CDMO Sterile Injectable business for new lines in the Spokane facility. We expect to reach peak utilisation for Line 3 in 3 years from start of commercial production vs 4 years, expected earlier."
Meanwhile, the companys board recommended a final dividend of Rs 5 per share of Re 1 each for FY25. The dividend, if approved by the shareholders, will be paid within 30 days from the date of the Annual General Meeting. The company has fixed the record date as Friday, 25 July 2025, for the purpose of final dividend payment.
Jubilant Pharmova is a globally present company engaged in radiopharmaceuticals, allergy immunotherapy, CDMO sterile injectables, contract research, development and manufacturing (CRDMO), generics, and proprietary novel drugs businesses.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
23 minutes ago
- Time of India
Maharashtra IT department emerges as primary cloud service provider for govt departments
Pune: Maharashtra's Information Technology Corporation Ltd (MahaIT) has become the main cloud service provider for govt departments. Senior state IT officials confirmed that several departments have already began migrating their data to MahaIT's cloud platform, marking a strategic shift in the state's data management approach. Tired of too many ads? go ad free now "It is a win-win situation — departments gain peace of mind regarding data safety and security, while we strengthen our capabilities in cloud services," said an official. The move has come in the aftermath of a major controversy earlier this year when MahaIT filed a criminal complaint against a private cloud vendor and its directors over alleged extortion and threats to delete sensitive govt data. The FIR accused the firm of breaching contract terms and blocking access to services for eight departments after invoicing for undelivered services. The matter escalated to Bombay High Court, which directed affected departments to transfer their data to MahaIT's cloud. Launched under Maharashtra's 2018 public cloud policy — the first of its kind in India — the state mandated all govt departments to store data on cloud platforms, opening a Rs 200 crore opportunity for cloud service providers. However, concerns over security and vendor reliability have since prompted a greater push for in-house cloud solutions. Currently, MahaIT is in discussion with multiple departments to broaden cloud adoption on its platform, aiming to consolidate govt data under a single, secure service provider. Many departments, such as the state registration department, the agriculture department, and many others, have shifted to cloud. "There are several departments that are already using cloud services. We will reach out to all departments and put across our services,'' an IT official added.
Economic Times
28 minutes ago
- Economic Times
RBI's next interest rate cut action likely in December
Reserve Bank of India may keep interest rates steady in August. However, further reduction is expected later this year. This follows a larger-than-expected cut aimed at boosting economic growth. Most institutions anticipate a rate cut in either October or December. The central bank will also lower the cash reserve ratio to inject liquidity. These measures surprised the markets. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The Reserve Bank of India (RBI) is expected to hold interest rates in August but possibly make yet another reduction later this year, following its greater-than-expected cut on Friday aimed at bolstering growth.A poll by ET showed that eight out of 10 institutions expect a rate cut either in October or December while two do not expect any reduction until December. All participants expect a pause in August. Nomura is the only participant anticipating a25 bps rate cut in the October and December policy reviews. The next meeting of the RBI Monetary Policy Committee (MPC) is scheduled for August 4-6. A basis point is 0.01 percentage RBI announced a 50 bps reduction in the key repo rate to 5.50% — against expectations of a 25 bps cut — and shifted its stance to 'neutral' from 'accommodative'.Since then, economists and market participants have been debating the extent of further rate cuts that the central bank may take and by when, given governor Sanjay Malhotra's statement that monetary policy was left with limited space to support growth after having reduced the repo rate by 100 bps since February. He added that the future course of action by the MPC will be data other factors could come into play later in the year. 'The combination of a 50 bps repo rate cut and a shift in stance to neutral is a signal that the space for policy easing has been largely exhausted,' Nomura said. 'However, the policy outlook depends on the macro outlook. Beyond an August pause, we expect the easing cycle to continue and still see 5.00% as the terminal rate.'Possible uncertainties include the June-September monsoon, US tariffs and their impact on growth and the potential for inflation to come in below projections. Despite challenges, there's room for further reduction in the RBI's repo rate, most participants said. The monsoon made landfall earlier than scheduled and while the weather office has said it will be above normal, there's been a lull in rain in some parts of the country since then. Other areas have been hit by severe RBI will also lower the cash reserve ratio by 50 bps to 3% in phases, starting September, to infuse Rs 2.5 lakh crore liquidity in the system. Both measures — the extent of the rate cut and the CRR reduction — caught the markets off guard. 'Everything that had been forecast for this calendar year happened in one policy,' a bond trader said, reflecting the market's mood after the June 6 monetary policy the governor's statement on the limited space to support growth, some economists said the RBI is not just responding to short-term data, but is also aiming to help the Indian economy grow at its full potential. Malhotra has said that the aspiration is to grow at 8%, more than 6.5% projected by the central bank for FY26.
Time of India
37 minutes ago
- Time of India
City's goat markets record sales to nearly 400 crore this Bakrid
Lucknow: The city's sacrificial animal market this Eid-ul-Azha recorded goat sales reaching approximately Rs 400 crore. Over the past six days, just two major markets—Dubagga and under Khadra Bridge—alone recorded sales exceeding Rs 40 crore worth of goats. The markets saw large crowds as buyers and sellers engaged actively, turning the religious festival into a significant economic event in the city. The bustling trade not only fulfilled traditional religious needs, but also gave a notable boost to local commerce. Several traders from the city, nearby districts and other states came to the various markets. According to traders and managers of temporary goat market near Joggers Park Dubagga and Pakka Pul, Khadra, around three lakh Muslims out of the city's approximately 9.5 lakh Muslim population participated in this year's Qurbani, purchasing goats that averaged around Rs 15,000 to Rs 5 lakh. In the Dubagga and Khadra markets alone, sales worth Rs 60 crore were recorded over the last six days. Organiser and manager of the Dubagga Goat Market, Mohammad Jamal, said, "In the last three days, goat trades worth nearly Rs 60 crore took place at the Dubagga market, with buyers arriving from various parts of the city and nearby places. On the final day before Eid-ul-Azha, till the early hours of June 7, transactions of around Rs 5 crore were recorded. This year, the market witnessed a significant increase in footfall and demand, especially for premium breeds. " M oreover, another temporary market set up near Pakka Pul saw a significant footfall of buyers of sacrificial goats. Buyers were more interested in purchasing multiple goats instead of costly goats. Meanwhile, the sellers of green leaves and other food items for goats also saw a surge in their business. Mohammad Aamir, manager at Pakka Pul Mandi, highlighted, "This year, people were more interested in purchasing multiple goats instead of heavy and costly goats. Approximately Rs 25 crore of business was done in the last week before Eid-ul-Azha." "Not only goats increased the sales figure, but the vendors of food and green leaves for goats also had significant business," he added. Raju Baheliya, a leaves seller, said, "We used to sell leaves for goats all year round for fixed customers. However, in this season, we sell leaves 24X7 due to high demand." Anwar Shafi, a goat buyer at Pakka Pul, stated, "This festival is directly related to the rural economy." 'Sikandar' fetches Rs 3.5L:Goat named Sikandar sold for Rs 3.5 lakh and goat named Tiger sold for Rs 2.75 lakh. Meanwhile, Sheep (Dumba) sold for 1.75 lakh.
